| ID | 119128 |
| Author |
Okada, M
Sakamoto Hospital
Iwatsuki, N
Sakamoto Hospital
Sakamoto, K
Sakamoto Hospital
Ogawa, T
Sakamoto Hospital
|
| Keywords | imeglimin (Twymeeg)
type 2 diabetes (T2D)
Trials of Imeglimin for Efficacy and Safety (TIMES)
oral hypoglycemic agent (OHA)
Metformin
|
| Content Type |
Journal Article
|
| Description | Background: Imeglimin (Twymeeg) is latest focus of oral hypoglycemic agent (OHA).
Case presentation: Current case is 69-year-old male with type 2 diabetes (T2D) for 18 years. Result: HbA1c value increased to 7.6% in Sept 2022, and then metformin 750mg/day was changed to imeglimin 2000mg/day. HbA1c decreased to 6.9% for 4 months. Discussion and conclusion: Large study of Trials of IMeglimin for Efficacy and Safety (TIMES) showed beneficial efficacy for combined treatment of OHAs. Imeglimin has dual effects increasing insulin secretion and reducing insulin resistance. Perspectives concerning pharmacological effects of metformin and imeglimin are described in diabetic practice and research. |
| Journal Title |
International Journal of Endocrinology and Diabetes
|
| ISSN | 26943875
|
| Publisher | Pubtexto Publishers
|
| Volume | 6
|
| Issue | 1
|
| Start Page | 145
|
| Published Date | 2023-02-05
|
| Rights | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| DOI (Published Version) | |
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
